Investigating factors affecting PD-L1 testing in cancer patients
Official title: Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients
Funded at Beth Israel Deaconess Medical Center · NIH-11000384 · Data updated 2026-11-12
This study is working on a new test to better measure a protein called PD-L1 in cancer tissues, which helps doctors find out if certain patients might benefit from immunotherapy, using small samples from biopsies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2023 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $220,834 |
| NIH project number | 5U01CA263986-04 |
| Project ID | NIH-11000384 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with malignancies such as melanoma, lung cancer, bladder cancer, or gastroesophageal cancer who are undergoing PD-L1 testing.
✕Less likely to help
Patients with cancers not associated with PD-L1 testing or those who are not candidates for immunotherapy may not benefit from this research.
What this research studies
This research focuses on improving the accuracy of predictive biomarker assays for PD-L1 protein expression in tumor tissues, which is crucial for identifying cancer patients who may benefit from immunotherapy. The study aims to develop a multiplexed immunohistochemical assay that can assess PD-L1 alongside other tissue markers from small biopsy samples. By examining patient-specific factors and pre-analytical variables that may influence test results, the research seeks to enhance the reliability of PD-L1 testing, which is vital for effective cancer treatment decisions.
Why it matters
Potential benefit: If successful, this research could lead to more accurate identification of patients who are likely to respond to immunotherapy, improving treatment outcomes.
How similar studies have gone: Previous research has shown promise in improving biomarker assays for cancer therapies, indicating that this approach could yield significant advancements.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Roehrl, Michael H. a. — Beth Israel Deaconess Medical Center
- Study coordinator: Roehrl, Michael H. a.
Related research
Other NIH-funded projects on the same topics.
-
SATURN MRI ancillary study: statins after intracerebral hemorrhage and brain MRI markers
This study looks at what happens to brain MRI markers and health outcomes when people with a specific type of brain bleed continue or stop taking statins.
-
Statin use after brain bleed MRI study in ICH patients (SATURN MRI) Ancillary Study
This project tests whether continuing or stopping statin therapy after an intracerebral hemorrhage affects brain changes seen on MRI and related health outcomes in people with lobar ICH.
-
Statin use after brain bleed: SATURN MRI ancillary study
This project tests whether continuing statin medicines after a brain bleed (lobar intracerebral hemorrhage) affects new brain blood vessel findings and long-term health.
-
XenCAT: Single Cell Atlas for Xenopus
Aims to map gene activity at the single-cell level in Xenopus to help understand how cells develop and how this relates to human disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.